Top

European Radiology

Published in:

01-07-2011 | Cardiac

Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation

Authors: Petri Sipola, Jarkko Magga, Minna Husso, Pertti Jääskeläinen, Keijo Peuhkurinen, Johanna Kuusisto

Published in: European Radiology | Issue 7/2011

Abstract

Objective

To evaluate the value of cardiac magnetic resonance imaging (CMRI)-assessed left ventricular hypertrophy (LVH) in differentiating between hypertensive heart disease and hypertrophic cardiomyopathy (HCM).

Methods

95 unselected subjects with mild-to-moderate hypertension, 24 patients with HCM attributable to the D175N mutation of the α-tropomyosin gene and 17 control subjects were studied by cine CMRI. Left ventricular (LV) quantitative and qualitative characteristics were evaluated.

Results

LV maximal end-diastolic wall thickness, wall thickness-to-LV volume ratio, end-diastolic septum thickness and septum-to-lateral wall thickness ratio were useful measures for differentiating between LVH due to hypertension and HCM. The most accurate measure for identifying patients with HCM was the LV maximal wall thickness ≥17 mm, with a sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 90%, 93%, 86%, 95% and 91%, respectively. LV maximal wall thickness in the anterior wall, or regional bulging in left ventricular wall was found only in patients with HCM. LV mass index was not discriminant between patients with HCM and those with LVH due to hypertension.

Conclusion

LV maximal thickness measured by CMRI is the best anatomical parameter in differentiating between LVH due to mild-to-moderate hypertension and HCM attributable to a sarcomeric mutation. CMRI assessment of location and quality of LVH is also of value in differential diagnosis.

Verdecchia P, Carini G, Circo A et al (2001) Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 38:1829–1835PubMedCrossRef

Gardin JM, Lauer MS (2004) Left ventricular hypertrophy: the next treatable, silent killer? JAMA 292:2396–2398PubMedCrossRef

Elliott P, McKenna WJ (2004) Hypertrophic cardiomyopathy. Lancet 363:1881–1891PubMedCrossRef

Belenkov Y, Vikhert OA, Belichenko OI, Arabidze GG (1992) Magnetic resonance imaging of cardiac hypertrophy in malignant arterial hypertension. Am J Hypertens 5:195S–199SPubMed

Keller H, Wanger KC, Goepfrich M, Stegaru B, Buss J, Heene DL (1990) Morphological quantification and differentiation of left ventricular hypertrophy in hypertrophic cardiomyopathy and hypertensive heart disease. A two dimensional echocardiographic study. Eur Heart J 11:65–74PubMed

Afonso LC, Bernal J, Bax JJ, Abraham TP (2008) Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. JACC Cardiovasc Imaging 1:787–800PubMedCrossRef

Sparrow P, Merchant N, Provost Y, Doyle D, Nguyen E, Paul N (2009) Cardiac MRI and CT features of inheritable and congenital conditions associated with sudden cardiac death. Eur Radiol 19:259–270PubMedCrossRef

Wagner S, Auffermann W, Buser P, Semelka RC, Higgins CB (1991) Functional description of the left ventricle in patients with volume overload, pressure overload, and myocardial disease using cine magnetic resonance imaging. Am J Card Imaging 5:87–97PubMed

Petersen SE, Selvanayagam JB, Francis JM et al (2005) Differentiation of athlete’s heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 7:551–558PubMedCrossRef

10.

Puntmann VO, Jahnke C, Gebker R et al (2010) Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol 106:1016–1022PubMedCrossRef

11.

Thierfelder L, Watkins H, MacRae C et al (1994) α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77:701–712PubMedCrossRef

12.

Jääskeläinen P, Miettinen R, Kärkkäinen P, Toivonen L, Laakso M, Kuusisto J (2004) Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med 36:23–32PubMedCrossRef

13.

Bos JM, Towbin JA, Ackerman MJ (2009) Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 54:201–211PubMedCrossRef

14.

Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536PubMed

15.

Vottonen P, Husso M, Sipola P, Vanninen R, Peuhkurinen K, Magga J (2007) Electrocardiographic left ventricular hypertrophy has low diagnostic accuracy in middle-aged subjects. Blood Press 16:328–334PubMedCrossRef

16.

Schiller NB, Shah PM, Crawford M et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367PubMed

17.

Sipola P, Lauerma K, Jaaskelainen P et al (2005) Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene. Radiology 236:815–824PubMedCrossRef

18.

McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M (1997) Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77:130–132PubMed

19.

Dulce MC, Mostbeck GH, Friese KK, Caputo GR, Higgins CB (1993) Quantification of the left ventricular volumes and function with cine MR imaging: comparison of geometric models with three-dimensional data. Radiology 188:371–376PubMed

20.

Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098PubMed

21.

Salton CJ, Chuang ML, O’Donnell CJ et al (2002) Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 39:1055–1060PubMedCrossRef

22.

Rickers C, Wilke NM, Jerosch-Herold M et al (2005) Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 112:855–861PubMedCrossRef

23.

Olivotto I, Maron MS, Autore C et al (2008) Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 52:559–566PubMedCrossRef

24.

Marian AJ, Roberts R (2001) The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 33:655–670PubMedCrossRef

25.

Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P (2003) Molecular genetics of familial hypertrophic cardiomyopathy (FHC). J Hum Genet 48:55–64PubMedCrossRef

26.

Strijack B, Ariyarajah V, Soni R et al (2008) Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype. J Cardiovasc Magn Reson 10:58PubMedCrossRef

27.

Maron MS, Maron BJ, Harrigan C et al (2009) Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 54:220–228PubMedCrossRef

28.

Grothues F, Smith GC, Moon JC et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29–34PubMedCrossRef

29.

Germans T, Russel IK, Gotte MJ, et al (2010) How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 12:13

30.

Rudolph A, Abdel-Aty H, Bohl S et al (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy: Relation to remodeling. J Am Coll Cardiol 53:284–291PubMedCrossRef

Title: Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation
Authors: Petri Sipola
Jarkko Magga
Minna Husso
Pertti Jääskeläinen
Keijo Peuhkurinen
Johanna Kuusisto
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: European Radiology / Issue 7/2011
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-011-2065-y

At a glance: The STEP trials

Springer Medicine

Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation

Abstract

Objective

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2011

Pulmonary langerhans cell histiocytosis in adults: high-resolution CT—pathology comparisons and evolutional changes at CT

Erratum to: Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants

Normal parenchymal enhancement patterns in women undergoing MR screening of the breast

Diagnostic benefits of presurgical fMRI in patients with brain tumours in the primary sensorimotor cortex

Letter to the editor re: low-dose computed tomography of the paranasal sinus and facial skull using a high-pitch dual-source system—First clinical results

Prosthetic heart valve assessment with multidetector-row CT: imaging characteristics of 91 valves in 83 patients